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Abstract
There is overwhelming evidence that optimal adjuvant endocrine therapy for hormone sensitive
breast cancer in postmenopausal women should include a third generation aromatase inhibitor
(AI). On current evidence, adjuvant anstrozole or letrozole should be used upfront in such patients
especially in those with high risk disease (node positive and/or tumours > 2 cm). The sequential
approach of tamoxifen for 2–3 years followed by exemestane or anastrozole for 2–3 years is a
reasonable alternative to 5 years of AI monotherapy in patients with low risk disease (node
negative and tumour smaller than 2 cm) especially if the tumour is positive for estrogen and
progesterone receptors.
Node-positive patients completing 5 years of adjuvant tamoxifen should be offered letrozole for up
48 months. Further research is required to establish the long-term cardiovascular safety of AIs
especially that of letrozole and exmestane, the optimal AI to use, duration of AI therapy and
whether monotherapy with an AI for 5 years is superior to sequencing an AI after 2–3 years of
tamoxifen.
The bone mineral density (BMD) should be measured at baseline and monitored during therapy in
women being treated with AIs. Anti-osteoporosis agents should such as bisphosphonates should
be considered in patients at high risk of bone fractures.
Background
Anti-aromatase drugs inhibit the cytochrome p-450 com-
ponent of the aromatase enzyme complex responsible for
the final step of estrogen biosynthesis in peripheral tis-
sues. Third-generation aromatase inhibitors (anastrozole,
letrozole, and exemestane) are now considered the gold
standard endocrine therapy in the first-line and second-
line settings for estrogen receptor (ER) and/or progester-
one receptor (PgR) positive advanced breast cancer in
postmenopausal women [1]. Furthermore there is a grow-
ing body of evidence for their superiority to tamoxifen in
the adjuvant setting. The latter is the focus of this article.
Several studies have shown that aromatase inhibitors
(AIs) are superior to tamoxifen in the adjuvant setting for
postmenopausal women with ER positive breast cancer
during the first 5 years.
Anastrozole
The ATAC (Arimidex, Tamoxifen, Alone or in Combina-
tion) study [2] has shown that 5 years of anastrozole is
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superior to tamoxifen in terms of efficacy and tolerability
in treating postmenopausal women with ER positive
breast cancer. After a median follow-up of 68 months,
(9366 postmenopausal women with localised breast can-
cer), anastrozole significantly prolonged disease-free sur-
vival (DFS) and reduced the risk of recurrence by 26% in
patients with hormone-receptor positive disease [hazard
ratio = 0.74, 95% CI 0.64–0.87, p = 0.0002]. There was a
12% statistically non-significant reduction in breast can-
cer-related deaths in the anastrozole group compared to
tamoxifen and a reduction of borderline significance in
distant metastases (hazard ratio: 0.84, p = 0.056). How-
ever, no significant difference in overall survival (OS) was
seen after 68 months. This may be due to the fact that the
follow-up interval is currently too short to see such a dif-
ference. However, another potential contributing factor to
the similarity in OS is the increase in non-breast cancer
deaths in the anastrozole group. The latter was largely due
to an excess of new non-breast cancers (statistically non-
significant). There was no significant difference between
the two groups in relation to the incidence of cardiac mor-
tality, myocardial infarction (MI) or ischaemic heart dis-
ease (IHD) suggesting no adverse cardiac effect for
anastrozole compared with tamoxifen which is consid-
ered cardio-protective. The incidence of deep venous
thrombosis (DVT) [1.6% vs. 2.4%, p = 0.02], stroke (odds
ratio = 0.7; 95% CI = 0.50–0.97), contralateral breast can-
cer and endometrial tumours was lower in women taking
anastrozole compared with tamoxifen. However, anastro-
zole use was associated with a higher incidence of hyper-
cholesterolemia, arthralgia, osteoporosis and fractures
(11.0% vs. 7.7%, p < 0.0001) compared with tamoxifen.
The latter observation underscores the importance of
determining BMD at baseline and monitoring it during
therapy. Anti-osteoporosis agents such as bisphospho-
nates can be used for prevention or treatment as required.
The ATAC study [2] has therefore recommended a 5-year
initial course of anastrozole instead of tamoxifen espe-
cially in women with ER+ve and PgR-ve breast cancer. This
recommendation has been also based on the observation
that the hazard of recurrence is highest in the first two
years especially in patients with node positive disease and
the benefit is greatest in women with ER+ve and PgR-ve
breast cancer [3]. Surprisingly however no significant ben-
efit was seen in node positive patients and those who had
received chemotherapy in subgroup analyses. Further-
more, the observation that women with ER+ve and PgR-ve
breast cancer derive a greater benefit from adjuvant AI
therapy has not been replicated in other adjuvant AI trials.
Letrozole
The Breast International Group (BIG) 1–98 study is a ran-
domized, phase III, double-blind trial comparing five
years of treatment with various adjuvant endocrine ther-
apy regimens in postmenopausal women with hormone-
receptor-positive breast cancer: letrozole, letrozole fol-
lowed by tamoxifen, tamoxifen, and tamoxifen followed
by letrozole [4]. The analysis comparing the two groups
assigned to receive letrozole initially with the two groups
assigned to receive tamoxifen initially has been recently
published. A total of 8010 women with assessable data
were enrolled, 4003 in the letrozole group and 4007 in
the tamoxifen group. After a median follow-up of 25.8
months, the five-year DFS estimates were 84.0% and
81.4%, respectively. Letrozole significantly reduced the
risk of recurrence by 28% with hormone-receptor positive
disease (hazard ratio = 0.72; 95% CI = 0.61 to 0.86; P <
0.001), especially the risk of distant recurrence (hazard
ratio = 0.73; 95% CI, 0.60 to 0.88; P = 0.001). This risk
reduction of distant relapse is greater than that seen with
anastrozole in the ATAC study, however caution should
be exercised when considering such a cross-trial compari-
son. Thromboembolism, endometrial cancer, contralat-
eral breast cancer and vaginal bleeding were more
common in the tamoxifen group. Women given letrozole
had a higher incidence of fractures (5.7% vs. 4.0%, p <
0.001) indicating the need for the measurement and
monitoring of BMD. Furthermore the incidence of cardio-
vascular events (excluding thrombo-embolism) such as
grade 3–5 cardiac failure (2.1% vs. 1.1%, p = 0.0003) and
hypercholesterolemia was also higher among women
given letrozole. Therefore longer follow up is required in
order to assess the long term safety of letrozole especially
regarding the cardiovascular system. The incidence of cer-
ebro-vascular events (1%) was similar in both groups.
Unlike the ATAC study, subgroup analyses of BIG1-98
showed a significant DFS benefit in favour of letrozole
among high risk groups such as patients with node posi-
tive breast cancer and/or tumours larger than 2 cm. Fur-
thermore, the letrozole benefit was seen in all ER+ cases
regardless of PgR status highlighting the limitations of
subgroup analyses in large trials.
The switching/sequencing approach
Two recent studies [5,6] which switched patients from
tamoxifen to an AI after 2–3 years showed a significant
improvement in 5-year DFS. In the well-designed Interna-
tional Exemestane Study (IES) which recruited 4742
patients, the adjusted hazard ratio for DFS was 0.63 (95%
CI = 0.51–0.77, p = 0.00001) in favour of exemestane,
suggesting that patients benefit from using both drugs
sequentially. The distant DFS but not OS was also signifi-
cantly better in the exemestane arm compared with
tamoxifen (HR = 0.66, p = 0.00004, HR = 0.88, p = 0.37
respectively). Osteoporosis, visual disturbances and
arthralgia were more frequently seen with exemestane (p
= 0.05, 0.04 and 0.01 respectively) whereas thromboem-
bolism, vaginal bleeding, contralateral breast cancer andInternational Seminars in Surgical Oncology 2006, 3:31 http://www.issoonline.com/content/3/1/31
Page 3 of 4
(page number not for citation purposes)
other non-breast primary cancers were more frequent in
the tamoxifen arm. Although the incidence of MI was
increased in the exemestane group compared with
tamoxifen arm (20 vs. 8 MIs, p = 0.023), there was differ-
ence in cardiac mortality between the two groups. An
update of the IES has been recently presented at The Amer-
ican Society of Clinical Oncology (June 2006). After a
median a follow up of 4.8 years, there was no statistically
significant OS benefit in favour of the switch as initially
predicted (OS benefit = 15%, p = 0.08).
Jonat et al [7] have recently analyzed patient data on
4,009 postmenopausal women enrolled in three studies –
Arimidex-Nolvadex (tamoxifen) 95 (ARNO 95), the Aus-
trian Breast & Colorectal Cancer Study Group 8 (ABCSG-
8), and the Intergroup Tamoxifen Anastrozole (ITA) trial.
All of the studies showed benefits in terms of DFS for
women who had switched to Arimidex after two or three
years of tamoxifen. The meta-analysis (the median follow-
up on all the studies was 30 months), though, showed an
OS advantage in favour of the switch. The hazard ratio for
death was 0.71 with a 95% confidence interval ranging
from 0.52 to 0.98 for the meta-analysis data. The meta-
analysis also showed that the group that switched had a
41% improvement in DFS (hazard ratio = 0.59, p-value
less than 0.0001) and significantly longer time to any
recurrence.
It is important to note that both switch studies' patients
were disease-free at the time of randomisation to either
continued tamoxifen or an AI (i.e. disease-free at 2–3
years of follow-up), thus making any direct comparison
with AI monotherapy trials invalid.
The potential advantages of the switching approach
include the bone protection and cholesterol lowering
effect conferred by tamoxifen prior to starting an AI. It
remains to be proven whether a sequencing approach will
lead to a reduction in fractures and ischaemic heart dis-
ease. Data from the bone sub-protocol of the IES show
that the gain in bone mineral density (BMD) in patients
treated with tamoxifen for 2–3 years is lost rapidly after
starting an AI. Differences in BMD appear within six
months of switching, and the loss is similar to that seen
with other AIs at 2–3% in the first year of therapy with
exemestane. Such observations underscore the impor-
tance of BMD monitoring and preventative intervention
in patients taking an AI.
Using Markov models to simulate 10-year DFS among
postmenopausal women with ER positive breast cancer,
Punglia et al [8], analysed three treatment strategies: 5
years of tamoxifen alone, 5 years of an AI alone, and
sequential treatment consisting of tamoxifen with cross
over to an AI at 2.5 or 5 years. The authors found that
sequential therapy with tamoxifen followed by cross over
to an AI at 2.5 years yielded a significant improvement in
DFS compared with planned AI monotherapy. At 10
years, the cross-over strategy achieved absolute DFS rates
of 83.7% and 67.6% for node-negative and node-positive
patients, respectively, compared with 82.6% and 65.5%,
respectively, for AI monotherapy, which is a 6% relative
risk reduction. The DFS improvement was apparent after
6 years. Later cross over from tamoxifen to an AI at 5 years
did not further improve 10-year DFS estimates. This anal-
ysis suggests that sequential treatment could be superior
to AI mono-therapy in terms of DFS. However, this model
used heterogeneous end-points from different trials and
assumed constant recurrence rates.
Contradicting conclusions were reached by a different
model constructed by Cuzick et al [9] who concluded that
the switching strategy will be always inferior to 5 years of
AI monotherapy. This model assumed phenotypic recep-
tor remodelling and a constant benefit from AIs over 10
years.
Since such models are based on certain assumptions, the
question whether 5 years of AI monotherapy is superior or
inferior to sequential teerapy approach can be only
answered by RCTs. Results from the ongoing arms of the
Big 1–98 study, which are expected to determine whether
mono-therapy or sequential therapy is more effective, and
if sequential therapy, which sequence is more effective,
are expected in 2008.
Extended adjuvant
Furthermore postmenopausal women completing 5 years
of adjuvant tamoxifen, letrozole has been shown to be of
value in reducing breast cancer recurrence (p < 0.0001)
when given in the extended adjuvant therapy (up to 48
months of treatment) setting in the MA.17 study [10]. The
latter is a double-blind placebo-controlled trial involving
5187 postmenopausal women who had completed 5
years of tamoxifen. Furthermore, this study showed a sig-
nificant OS benefit in patients with node-positive disease
(n = 2360, p = 0.038).
Contralateral breast cancer
It should be noted that all three AIs were found to be supe-
rior to tamoxifen in reducing the risk of contralateral
breast cancer [2,4,5] indicating that tamoxifen is a subop-
timal chemopreventative strategy.
Costeffectiveness
Finally in relation to cost-effectiveness, it has been esti-
mated that tamoxifen for 2–3 years followed by an AI
achieves the lowest cost/QALY estimates, a further
improvement of DFS of 1% if the AI is given up front pro-
vides an acceptable cost/QALY. However, the additionalPublish with BioMed Central    and   every 
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benefits achieved by administering an AI subsequent to 5
years of tamoxifen seem to provide unacceptable costs
[11].
Conclusion
￿ Optimal adjuvant endocrine therapy for hormone sensi-
tive breast cancer in postmenopausal women should
include an AI.
￿ Adjuvant anstrozole or letrozole should be used upfront
in such patients especially in those with high risk disease
(node positive and/or tumours > 2 cm).
￿ The sequential approach of tamoxifen for 2–3 years fol-
lowed by exemestane or anastrozole for 2–3 years is a rea-
sonable alternative to 5 years of AI monotherapy in
patients with low risk disease (node negative and tumour
smaller than 2 cm) especially if the tumour is positive for
estrogen and progesterone receptors.
￿ Node-positive patients completing 5 years of adjuvant
tamoxifen should be offered letrozole for up 48 months.
￿ The bone mineral density (BMD) should be measured at
baseline and monitored during therapy in women being
treated with AIs. Anti-osteoporosis agents should such as
bisphosphonates should be considered in patients at high
risk of bone fractures.
￿ Further research is required to establish the long-term
cardiovascular safety of AIs especially that of letrozole and
exmestane, the optimal AI to use, duration of AI therapy
and whether monotherapy with an AI for 5 years is supe-
rior to sequencing an AI after 2–3 years of tamoxifen.
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